Zonisade (Zonisamide) Patent Expiration, LOE Window & CMS Spending
Zonisade (Zonisamide) by Azurity: FDA Orange Book LOE 2038-08-18, 7 AB generics, $26.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Azurity |
| FDA Application & Pathway | N214273 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2038-08-18 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 7 |
| 2024 CMS Total Public Spend | $26.6M |
| 2024 Medicare Part D Spend | $4.4M |
| 2024 Medicaid Spend | $22.2M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 23.5% 2-yr change) |